Review
Biochemistry & Molecular Biology
David Escors, Ana Bocanegra, Luisa Chocarro, Ester Blanco, Sergio Pineiro-Hermida, Maider Garnica, Leticia Fernandez-Rubio, Ruth Vera, Hugo Arasanz, Grazyna Kochan
Summary: PD-L1/PD-1 blockade immunotherapy has revolutionized cancer treatment, but its mechanisms and effectiveness are still not fully understood. This article reviews the evidence supporting the role of CD4 T cells in anti-tumor immunity and their potential as predictors of response to PD-L1/PD-1 blockade immunotherapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biochemistry & Molecular Biology
Kai Hou, Xiaohui Xu, Xin Ge, Jiacen Jiang, Fan Ouyang
Summary: Immune checkpoints play a role in promoting tumor growth and inhibiting immune-mediated cancer cell apoptosis. Targeting immune checkpoints has been successful in treating various cancers, including hepatocellular carcinoma (HCC). However, some patients do not respond to this therapy due to acquired resistance and recurrence. Understanding the specific mechanisms of immune checkpoints in HCC development is crucial for improving the efficacy of anti-PD-1 and anti-CTLA-4 therapy.
Article
Cell Biology
Mingyue Liu, Xu Wang, Xuexiang Du, Wei Wu, Yan Zhang, Peng Zhang, Chunxia Ai, Martin Devenport, Juanjuan Su, Musleh M. Muthana, Lishan Su, Yang Liu, Pan Zheng
Summary: Immune checkpoint inhibitors (ICIs) like nivolumab and ipilimumab show both antitumor responses and severe immune-related adverse events (irAEs), but treating irAEs without affecting the immunotherapeutic effect of ICIs remains a challenge. The use of abatacept to treat irAEs risks reducing the efficacy of anti-CTLA-4 immunotherapy. However, mutants of CTLA-4-Ig that bind to B7-1 and B7-2 can effectively treat irAEs without affecting cancer immunotherapy, making belatacept a potential drug to abrogate irAEs while preserving the therapeutic efficacy of CTLA-4-targeting ICIs.
SCIENCE TRANSLATIONAL MEDICINE
(2023)
Article
Medicine, Research & Experimental
Yujeong Moon, Man Kyu Shim, Jiwoong Choi, Suah Yang, Jinseong Kim, Wan Su Yun, Hanhee Cho, Jung Yeon Park, Yongju Kim, Joon-Kyung Seong, Kwangmeyung Kim
Summary: In this study, the researchers propose a new strategy to enhance cancer immunotherapy by using anti-PD-L1 peptide-conjugated prodrug nanoparticles (PD-NPs). The PD-NPs are taken up by cancer cells and release the drug, resulting in the disruption of immune-suppressing pathways and the enhancement of T lymphocyte immune responses. The results show that PD-NPs accumulate in tumor tissues and recruit a large amount of immune cells, leading to effective antitumor effects. This strategy has the potential to overcome the toxicity and low response rate issues in current cancer immunotherapy.
Article
Oncology
Satoshi Muto, Sho Inomata, Hikaru Yamaguchi, Hayato Mine, Hironori Takagi, Yuki Ozaki, Masayuki Watanabe, Takuya Inoue, Takumi Yamaura, Mitsuro Fukuhara, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Jun Osugi, Mika Hoshino, Mitsunori Higuchi, Yutaka Shio, Hiroyuki Suzuki
Summary: The proportions of CTLA-4(+) regulatory T cells to CD8 T cells and CTLA-4(+) cells in CD8 T cells were found to be irrelevant to the PD-L1 TPS in NSCLC patients.
ANTICANCER RESEARCH
(2021)
Review
Chemistry, Medicinal
Qi Zhang, Chenying Yang, Xingsu Gao, Ju Dong, Caiyun Zhong
Summary: This article discusses the role of immune checkpoint blockade in cancer treatment and explores the modulation of immune checkpoint proteins by phytochemicals and their combination effects with immune checkpoint inhibitors in various malignancies.
PHYTOTHERAPY RESEARCH
(2023)
Article
Oncology
Hikmat H. Assi, Chihunt Wong, Kimberly A. Tipton, Li Mei, Ken Wong, Jennifer Razo, Chanty Chan, Bruce Howng, Jason Sagert, Michael Krimm, Linnea Diep, Andrew Jang, Margaret T. Nguyen, Nicole Lapuyade, Victoria Singson, Ruth Villanueva, Madan Paidhungat, Shouchun Liu, Vangipuram Rangan, Olga Vasiljeva, James W. West, Jennifer H. Richardson, Bryan Irving, Dylan Daniel, Marcia Belvin, W. Michael Kavanaugh
Summary: Using protease-activatable antibody prodrugs (Pb-Tx) to locally inhibit PD-1/PD-L1 can reduce systemic immune toxicity while eliciting potent anti-tumor immune responses.
CANCER IMMUNOLOGY RESEARCH
(2021)
Article
Chemistry, Multidisciplinary
Jingmei Pan, Xilin Li, Binfen Shao, Funeng Xu, Xuehui Huang, Xing Guo, Shaobing Zhou
Summary: A nanocarrier that achieves self-blockade of PD-L1 in tumor cells and a detection kit to quantitatively measure the binding rate of PD-1/PD-L1 have been developed, improving the efficacy of PD-1/PD-L1 self-blocking therapy.
ADVANCED MATERIALS
(2022)
Review
Immunology
Meng Chen, Chenyan Li, Mingjun Sun, Yiling Li, Xuren Sun
Summary: This review summarizes the challenges in the treatment of gastroesophageal cancers (GECs) and the use of immune checkpoint inhibitors as a new therapeutic approach. Ongoing clinical trials with PD-1/PD-L1 pathway blockers in GEC are discussed, and further research is needed to apply them in the clinical care of patients. The review provides insights into the efficacy of PD-1/PD-L1 antibodies as a first-line treatment and in second-line or more treatment for GEC.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Allan Relecom, Maysaloun Merhi, Varghese Inchakalody, Shahab Uddin, Darawan Rinchai, Davide Bedognetti, Said Dermime
Summary: Immune checkpoint inhibitors have shown therapeutic benefits in solid cancers and some hematological malignancies, but predicting treatment response remains challenging. Studies on the dynamics of the immune system and tumor under immune checkpoint blockade have revealed mechanisms of action and adaptive resistance to these therapeutic agents.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Review
Chemistry, Analytical
Pei Wang, Longfei Tang, Bohui Zhou, Liangfen Cheng, Robert Chunhua Zhao, Juan Zhang
Summary: Immune checkpoints are a series of molecules that regulate the degree of immune activation, including PD-1/PD-L1, CTLA-4, LAG-3, and others. Immune checkpoint therapy is considered to be a safer and more effective treatment for tumor immunotherapy compared to conventional therapy. The analysis of immune checkpoints is crucial for immunotherapy medication, treatment, and prognosis evaluation.
TRAC-TRENDS IN ANALYTICAL CHEMISTRY
(2022)
Review
Oncology
Liming Liao, Huilin Xu, Yuhan Zhao, Xiaofeng Zheng
Summary: Immunotherapies based on immune checkpoint blockade have improved cancer therapy outcomes in the past decade. However, some patients show poor responsiveness to this therapy, and the underlying mechanism is not well understood. Recent studies have shown that targeting tumor metabolism in combination with immune checkpoint inhibitors provides new approaches to cancer therapy.
FRONTIERS OF MEDICINE
(2023)
Article
Oncology
Stefan Warmuth, Tea Gunde, Daniel Snell, Matthias Brock, Christopher Weinert, Alexandre Simonin, Christian Hess, Julia Tietz, Maria Johansson, Fabio Mario Spiga, Robin Heiz, Naomi Fluckiger, Sandro Wagen, Julia Zeberer, Dania Diem, Dana Mahler, Belinda Wickihalder, Simone Muntwiler, Bithi Chatterjee, Benjamin Kuttner, Bettina Bommer, Yasemin Yaman, Peter Lichtlen, David Urech
Summary: NM21-1480 is a tri-specific antibody-based molecule that targets tumor-infiltrating T cells, overcoming immune checkpoint resistance without causing liver toxicity. It shows promising pharmacokinetics and efficacy in preclinical studies.
Review
Oncology
Shuang Huang, Gang Zheng, Kai Yang
Summary: This systematic review and meta-analysis evaluated the efficacy and safety of neoadjuvant PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitors in malignant solid tumors. The results showed that the addition of CTLA-4 inhibitors did not significantly improve overall response rate and survival outcomes. However, there was an increased risk of grade 3-4 adverse events with the combination therapy. More large-scale and multicenter randomized controlled trials are needed to obtain more reliable results.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2023)
Review
Pharmacology & Pharmacy
Zikun Peng, Ming Li, Huayi Li, Qinglei Gao
Summary: Immune checkpoint inhibitors (ICIs) have revolutionized treatment in oncology, but have shown modest efficacy in ovarian cancer. This review summarizes clinical trials of PD-1/PD-L1 blockade in ovarian cancer, categorizes resistance mechanisms, and introduces candidate approaches to enhance the efficacy of anti-PD-1/PD-L1 antibodies by rewiring the tumor microenvironment (TME).
DRUG DISCOVERY TODAY
(2023)
